Abbott Laboratories (ABT) Q1 Earnings: Company Posts $544M Profit

Abbott Laboratories (ABT) Q1 Earnings: Company Posts $544M Profit
By Abbott LaboratoriesUploaded by Gump Stump at en.wikipedia [Public domain], via Wikimedia Commons

Abbott Laboratories (NYSE:ABT) reported its earnings before opening bell, meeting its guidance. The pharmaceutical company posted first-quarter profits of $544 million or 34 cents per share. Adjusted diluted earnings per share were 42 cents, which was toward the high end of the company’s guidance.

Play Quizzes 4

Abbott Laboratories (ABT) Q1 Earnings: Company Posts $544M Profit

Consensus for Abbott Laboratories (NYSE:ABT) was earnings per share of 41 cents on revenue of $5.42 billion. During the same quarter a year ago, the company posted net earnings of $351 million or 22 cents per share.

This Too Value Fund Explains Why Turkey Is Ripe For Investment Right Now

TurkeyThe Talas Turkey Value Fund returned 9.5% net for the first quarter on a concentrated portfolio in which 93% of its capital is invested in 14 holdings. The MSCI Turkey Index returned 13.1% for the first quarter, while the MSCI All-Country ex-USA was down 5.4%. Background of the Talas Turkey Value Fund Since its inception Read More

“Strong performance in Nutrition and Diagnostics, as well as overall results in emerging markets, led our sales growth this quarter,” said Chairman and CEO Miles D. White. “We had significant new product and geographic expansion activity during the quarter that positions Abbott well for continued growth.”

Abbott reported a 3.5 percent increase in worldwide sales excluding foreign exchange. Sales also jumped 1.8 percent, including the 1.7 percent unfavorable effect of foreign exchange. The drug maker reported a 9 percent increase in operational sales for its Nutrition segment, including 14.8 percent growth internationally. It also posted a 6.4 percent operational sales growth for its Diagnostics segment.

In emerging markets, Abbott posted $2.2 billion in sales during the first quarter, a 15.2 percent increase operationally. The company said sales in emerging markets make up over 40 percent of its total sales.

Abbott Laboratories (NYSE:ABT) said it launched a number of new products and began some new clinical trials during the first quarter. The company said it launched 19 new products in its Nutrition segment, a piece of automation equipment for laboratories and several diagnostic tests on the Architect platform.

In this morning’s report the company also declared a quarterly common dividend of 14 cents per share, which is payable May 15 to shareholders on record on April 15.

As of the moment of this writing, shares of Abbott Laboratories (NYSE:ABT) were down slightly pre-market.

Updated on

Michelle Jones is editor-in-chief for and has been with the site since 2012. Previously, she was a television news producer for eight years. She produced the morning news programs for the NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spent a short time at the CBS affiliate in Huntsville. She has experience as a writer and public relations expert for a wide variety of businesses. Email her at
Previous article Krugman, Cowen, Sumner Get it Wrong on on Wicksell
Next article Apple Inc. (AAPL) Street Expectations Too High For June: Munster

No posts to display